Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer
NJ 1808: Autophagic Cell Death With Hydroxychloroquine in Patients With Hormone-Dependent Prostate-Specific Antigen Progression After Local Therapy For Prostate Cancer.
Sponsor: National Cancer Institute (NCI)
Listed as NCT00726596, this PHASE2 trial focuses on Prostate Cancer and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 9 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jul 2022 — Jul 2024 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Jan 2021 — Jul 2022 [monthly]
Unknown Status PHASE2
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Feb 2017 — Feb 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Aug 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- Rutgers Cancer Institute of New Jersey
- Rutgers, The State University of New Jersey
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Hamilton, United States
- • Morristown, United States
- • New Brunswick, United States
- • Summit, United States
- • Voorhees Township, United States